Dyne Therapeutics Reports Sustained Functional Improvements in DM1…

Event summary

Dyne Therapeutics presented one-year data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1), showing functional improvements across multiple measures.
The pooled dose group (N=25-26) demonstrated a 3.2-second improvement in video hand opening time (vHOT) at 6 months, compared to a 0.4-second increase in the placebo group.
Topline data from the ACHIEVE registrational expansion cohort (REC) are expected in Q1 2027, with a potential Biologics License Application (BLA) submission for U.S. Accelerated Approval in Q3 2027.
The mean baseline vHOT in the ACHIEVE REC is 8.3 seconds, with topline data planned for Q1 2027.

The big picture

Dyne Therapeutics' latest data from the ACHIEVE trial underscores the potential of z-basivarsen to address the underlying splicing abnormalities in DM1, a rare and progressive neuromuscular disease with no approved disease-modifying treatments. The company's FORCE platform aims to deliver targeted therapeutic payloads to muscle and the central nervous system, positioning Dyne at the forefront of innovative approaches to genetic neuromuscular diseases. The upcoming regulatory milestones will be critical in determining the commercial viability of z-basivarsen.

What we're watching

Regulatory Pathway: Whether the U.S. FDA will accept video hand opening time (vHOT) as an intermediate clinical endpoint for accelerated approval of z-basivarsen.
Clinical Efficacy: The pace at which Dyne Therapeutics can confirm these findings through the ACHIEVE REC and the Phase 3 HARMONIA study.
Market Potential: How the sustained functional improvements in DM1 patients will position Dyne Therapeutics in the competitive landscape of rare disease treatments.